Evidence map›Paper›PMID 32828880›Full record

Trial reportAmerican journal of ophthalmology2021

SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.

Andrew Hendrick, Paul C VanVeldhuisen, Ingrid U Scott, Jacquie King, Barbara A Blodi, Michael S Ip, Rahul N Khurana, Neal L Oden, SCORE2 Investigator Group

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969708 (Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01969708 phase3completednot on this map

Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.

TypeinterventionalSponsorThe Emmes Company, LLCRan2014 to 2021Enrolled362ConditionsCentral Retinal Vein OcclusionArmsaflibercept, bevacizumab
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrew HendrickEmory University, Atlanta, Georgia, USA.
Paul C VanVeldhuisenThe Emmes Company, LLC, Rockville, Maryland, USA. Electronic address: score2@emmes.com.
Ingrid U ScottDepartments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Jacquie KingThe Emmes Company, LLC, Rockville, Maryland, USA.
Barbara A BlodiUniversity of Wisconsin Fundus Photograph Reading Center, Madison, Wisconsin, USA.
Michael S IpDoheny Eye Institute, University of California, Los Angeles, California, USA.
Rahul N KhuranaNorthern California Retina Vitreous Associates, Mountain View, California, USA.
Neal L OdenThe Emmes Company, LLC, Rockville, Maryland, USA.
SCORE2 Investigator Group

Funding

SCORE2 Comparative Trial (SCT)U10EY023533 · NEI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SCOTT, INGRID U · 2013 to 2018
$7.4M
SCORE2 Comparative Trial (SCT)U10EY023529 · NEI · THE EMMES COMPANY, LLC · PI VAN VELDHUISEN, PAUL C · 2013 to 2018
$6.8M
Intravitreal Corticosteroid for Macular EdemaU10EY014404 · NEI · THE EMMES COMPANY, LLC · PI VAN VELDHUISEN, PAUL C · 2003 to 2008
$3.8M
The SCORE2 Long-Term Follow-Up (SCORE2 LTF)UG1EY023533 · NEI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SCOTT, INGRID U · 2019 to 2021
$3.7M
SCORE2 Comparative Trial (SCT)U10EY023521 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI BLODI, BARBARA A · 2013 to 2018
$1.8M
NEI NIH HHS U10 EY014404NEI NIH HHS U10 EY023521NEI NIH HHS U10 EY023529NEI NIH HHS U10 EY023533NEI NIH HHS UG1 EY023533
6 · The paper itself

Abstract

purposeTo investigate the relationship between intraretinal macular hemorrhage and visual acuity outcomes in eyes with central retinal vein occlusion or hemiretinal vein occlusion managed with aflibercept, bevacizumab, or observation.

designRetrospective analysis of data from 2 randomized clinical trials.

methodsA total of 362 participants were randomized in the Study of Comparative Treatments for Retinal Vein Occlusion 2, and 88 participants randomized to observation in the Standard Care vs Corticosteroid in Retinal Vein Occlusion Study. Participants received monthly intravitreal aflibercept or bevacizumab through month 6 or observation through month 8. The main outcome was visual acuity letter score (VALS).

resultsReduced area of hemorrhage by month 6 was observed in 70.7% (116 of 164) of aflibercept-treated eyes, 63.8% (104 of 163) of bevacizumab-treated eyes, and 42.2% (27 of 64) of observation eyes by month 8 (P < .01). Relative to eyes with hemorrhage during follow-up, aflibercept-treated eyes without hemorrhage at month 6 had a mean VALS improvement of 8.0 (99% confidence interval [CI]: 1.9, 14.2); bevacizumab-treated eyes without hemorrhage at month 6 had a mean VALS improvement of 3.2 (99% CI: -4.6, 11.0); and observation eyes without hemorrhage at month 8 had a mean VALS improvement of 13.5 (99% CI: 0.4, 26.5). At month 6, the presence of hemorrhage and the change in central subfield thickness (CST) were significantly associated with the change in VALS; however, CST was a more important predictor.

conclusionImprovement in hemorrhage during follow-up was associated with visual acuity improvements and predicted visual acuity changes beyond what was explained by CST. These findings suggest that intraretinal macular hemorrhage is an important indicator of disease severity in retinal vein occlusion.

Indexed as

Angiogenesis InhibitorsBevacizumabFemaleHumansIntravitreal InjectionsMaleMiddle AgedReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinaRetinal HemorrhageRetinal Vein OcclusionRetrospective StudiesTomography, Optical CoherenceTreatment OutcomeafliberceptAngiogenesis InhibitorsBevacizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteins

Identifiers

PMID32828880
PMCPMC7895852

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.